The National Medical Products Administration (NMPA) has indicated on its website that four products will be switched from prescription-only to over-the-counter (OTC) status. The medications in question are desloratadine, loratadine, ambroxol, and naproxen. This move is part of ongoing efforts to make certain medications more accessible to the public.
Instructions for Marketing Authorization Holders (MAHs)
Relevant MAHs are advised to take prompt action in response to this change. They are required to submit revised instructions to their respective provincial drug regulatory departments. This must be done in accordance with the Drug Registration Regulation and other pertinent guidelines. The deadline for filing is set for January 22, 2024, underlining the urgency of the matter.
Notification Requirements for Healthcare Entities
Furthermore, MAHs are responsible for promptly notifying relevant medical institutions, drug operators, and other entities about the updated instructions. This ensures that all stakeholders are aware of the revised content and can adjust their practices accordingly.-Fineline Info & Tech
